Remote at the Federal Circuit, But Central to Pharma: Meeting the Enablement Requirement for Biotech Patents

In view of the Federal Circuit oral hearing in the Amgen v. Sanofi (No. 20-1074) case recently being scheduled for December 9, 2020, this webinar is being rescheduled to Wednesday, December 16, 2020. This new date will allow the speakers to provide a more comprehensive presentation with the benefit of oral arguments.

34th Annual Pharmaceutical/Chemical Patent Practice Update Webinar SeriesEarn up to 1.0 Professional CLE for NJ/NY/PA

Genus claims continue to be a focus of scrutiny by the courts. In Amgen v. Sanofi (No. 20-1074), the Federal Circuit is poised to decide yet another gateway issue concerning the patentability of biotech inventions. The court will consider whether two patents that claim a genus of antibodies satisfy the enablement requirement under 35 U.S.C. §112. Given that antibody technologies require a huge investment and are thought to be one of the most promising approaches to treat diseases today, the Federal Circuit’s forthcoming decision in Amgen v. Sanofi is likely to have a profound impact on the biotech industry.

Speakers
Clara N. Jimenez, Johnson & Johnson
Clara N. Jiménez is Senior Counsel in Johnson & Johnson’s IP Litigation Group which supports the J&J businesses in all aspects of intellectual property litigation across the globe. 

Preston K. Ratliff II, Paul Hastings
Preston K. Ratliff II is the Chair of the Firm’s Litigation practice in New York. Mr. Ratliff focuses his practice on complex, high-stakes patent litigation with an emphasis on the biotechnology, pharmaceutical, chemical, agricultural, and renewable fuel sectors. [Read more]

Moderators J. Eric Thies, Merck & Co., Inc. and Suja Vathyam, Botos Churchill IP Law LLP

GoToWebinar Note: Once you register, you will receive a GoToWebinar confirmation e-mail with a unique link to join the session. Click "Add to calendar" to ensure you don't miss the webinar.

Thank You To Our Sponsor

Chemical Practice Co-Chairs J. Eric Thies, Merck & Co., Inc. and Suja Vathyam, Botos Churchill IP Law LLP